Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : NEOTHERAPEUTICS (NEOT) (NEOTW) -- Ignore unavailable to you. Want to Upgrade?

To: David M. Evans who wrote (418)	5/26/1998 1:40:00 AM
From: Joe Bz	Respond to of 705

I wonder if Glasky learned his lesson about making "bold statements". Go back and read the initial interview with Glasky, read the clarification and read this. FROM News.com NeoTherapeutics' experience is similar to what happened to EntreMed Inc. after the New York Times reported on positive results of EntreMed's animal tests of its cancer drugs. Some investors are willing to bet against the odds that companies such as EntreMed and NeoTherapeutics will be able to move from early research to perhaps someday having drugs to sell. ''It's pure, pure speculation,'' said Steve Lisi, a biotechnology analyst at Mehta Partners. ''People who bought (NeoTherapeutics) at $18, I don't know what they were doing or what they were thinking.'' In a statement issued today, Irvine, California-based NeoTherapeutics said it would need additional funding to complete all the required tests of the drug.NeoTherapeutics' drug, called AIT-082, is in the second of three stages of testing required to apply for U.S. Food and Drug Administration approval. It will need to complete this stage successfully in order to move to more extensive tests. In its statement today, NeoTherapeutics also said it does not have a licensing agreement with a pharmaceutical company for the drug. Such agreements are common when a small biotechnology company has a promising drug.